HomeCompareNIMC vs JNJ

NIMC vs JNJ: Dividend Comparison 2026

NIMC yields 7.77% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NIMC wins by $26.2K in total portfolio value
10 years
NIMC
NIMC
● Live price
7.77%
Share price
$99.69
Annual div
$7.75
5Y div CAGR
13.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.5K
Annual income
$7,161.61
Full NIMC calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NIMC vs JNJ

📍 NIMC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNIMCJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NIMC + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NIMC pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NIMC
Annual income on $10K today (after 15% tax)
$660.80/yr
After 10yr DRIP, annual income (after tax)
$6,087.37/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, NIMC beats the other by $2,101.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NIMC + JNJ for your $10,000?

NIMC: 50%JNJ: 50%
100% JNJ50/50100% NIMC
Portfolio after 10yr
$43.4K
Annual income
$5,925.51/yr
Blended yield
13.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NIMC
Analyst Ratings
13
Buy
3
Hold
Consensus: Buy
Price Target
$50.00
-49.8% upside vs current
Range: $50.00 — $50.00
Altman Z
0.0
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NIMC buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNIMCJNJ
Forward yield7.77%2.13%
Annual dividend / share$7.75$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.9%28%
Portfolio after 10y$56.5K$30.3K
Annual income after 10y$7,161.61$4,689.40
Total dividends collected$30.2K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$50.00$228.73

Year-by-year: NIMC vs JNJ ($10,000, DRIP)

YearNIMC PortfolioNIMC Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,585$885.47$10,592$272.30+$993.00NIMC
2$13,488$1,092.01$11,289$357.73+$2.2KNIMC
3$15,786$1,353.37$12,123$472.89+$3.7KNIMC
4$18,577$1,686.03$13,141$629.86+$5.4KNIMC
5$21,990$2,112.08$14,408$846.81+$7.6KNIMC
6$26,190$2,661.28$16,021$1,151.60+$10.2KNIMC
7$31,397$3,374.04$18,122$1,588.22+$13.3KNIMC
8$37,901$4,305.74$20,930$2,228.20+$17.0KNIMC
9$46,087$5,532.79$24,792$3,191.91+$21.3KNIMC
10$56,475$7,161.61$30,274$4,689.40+$26.2KNIMC

NIMC vs JNJ: Complete Analysis 2026

NIMCStock

NiSource Inc., an energy holding company, operates as a regulated natural gas and electric utility company in the United States. It operates through two segments, Gas Distribution Operations and Electric Operations. The company distributes natural gas to approximately 853,000 customers in northern Indiana, as well as approximately 2.4 million residential, commercial, and industrial customers in Ohio, Pennsylvania, Virginia, Kentucky, and Maryland. It operates approximately 54,600 miles of distribution main pipelines, as well as associated individual customer service lines; and 1,000 miles of transmission main pipelines. The company generates, transmits, and distributes electricity to approximately 483,000 customers in 20 counties in the northern part of Indiana, as well as engages in wholesale electric and transmission transactions. It owns and operates coal-fired electric generating stations with a capacity of 722 megawatts (MW) in Wheatfield and 455 MW in Michigan City; combined cycle gas turbine with a capacity of 563 MW in West Terre Haute; natural gas generating units with a capacity of 155 MW in Wheatfield; hydro generating plants with a capacity of 9 MW in Carroll County and 7 MW in White County; and wind generating units with a capacity of 102 MW and 302 MW in White County, Indiana. The company was formerly known as NIPSCO Industries, Inc. and changed its name to NiSource Inc. in April 1999. NiSource Inc. was founded in 1847 and is headquartered in Merrillville, Indiana.

Full NIMC Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NIMC vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NIMC vs SCHDNIMC vs JEPINIMC vs ONIMC vs KONIMC vs MAINNIMC vs ABBVNIMC vs MRKNIMC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.